


Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claim 1-20 (cancelled)

21.(new) A compound having the formula I



I

wherein:

ring P is C₆₋₁₀aryl, C₃₋₇cycloalkyl, C₅₋₆heteroaryl, which ring P may be fused with phenyl, C₅₋₆heteroaryl, C₃₋₇cycloalkyl or C₃₋₇heterocycloalkyl;

R¹ is NO₂, NH₂, halo, N(C₁₋₆alkyl)₂, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, phenylC₀₋₆alkyl, C₅₋₆heteroarylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl, C₃₋₇heterocycloalkylC₀₋₆alkyl, C₁₋₆alkylOC₀₋₆alkyl, C₁₋₆alkylSC₀₋₆alkyl or C₁₋₆alkylNC₀₋₆alkyl;

n is 1, 2, 3, 4 or 5;

X is O, S or N;

R⁴ is H, C₁₋₄alkyl, hydroxyC₁₋₆alkyl or C₁₋₆alkylOC₁₋₆alkyl, or is absent when X is N;

R³ is H, C₁₋₆alkyl, C₁₋₆haloalkyl, R⁵OC₁₋₆alkyl, R⁵O(CO), R⁵CO, NR⁵R⁶CO, NR⁵R⁶C₀₋₆alkyl, C₂₋₆alkenylOC₀₋₆alkyl or hydroxyC₁₋₆alkyl;

R⁵ and R⁶ are at each occurrence independently selected from H, C₁₋₆alkyl, C₆₋₁₀aryl, C₅₋₆heteroaryl, C₁₋₄alkylSO₂ and C₁₋₃alkylCO;

R⁷ and R⁸ are independently selected from H, C₁₋₆alkyl, halo, cyano, C₁₋₆alkylOC₀₋₆alkyl, OH, NO₂ and COR⁹, N(R⁹)₂; and

R⁹ is H or C₁₋₆alkyl;

wherein any alkyl, alkylOalkyl, haloalkyl, haloalkylO, phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group may be substituted with one or more A, where A at each occurrence is

independently selected from OH, NO₂, R⁹CO, R⁹O(CO), N(R⁹)₂, R⁹S, R⁹SO₂, halo or C₁₋₆alkylOC₀₋₆alkyl,
or a salt, solvate or solvated salt thereof.

22.(new) A compound according to claim 21, wherein:

X is N;

R³ is H, C₁₋₆alkyl, C₁₋₆iodoalkyl, C₁₋₆bromoalkyl, C₁₋₆chloroalkyl, C₁₋₆alkylOC₀₋₆alkyl, R⁵OC₁₋₆alkyl, R⁵CO, R⁵CO₂, NR⁵R⁶CO, NR⁵R⁶C₀₋₆alkyl or C₂₋₆alkenylOC₀₋₆alkyl; and
R⁴ is H, C₁₋₄alkyl, hydroxyC₁₋₆alkyl or C₁₋₆alkylOC₁₋₆alkyl.

23.(new) A compound according to claim 21, wherein:

X is N;

R³ is C₁₋₆fluoroalkyl or hydroxyC₁₋₂alkyl, and

R⁴ is H.

24.(new) A compound according to claim 21, wherein:

X is O or S;

R³ is H, C₁₋₆alkyl, C₁₋₆haloalkyl, R⁵OC₁₋₆alkyl, R⁵O(CO), R⁵CO, NR⁵R⁶CO, NR⁵R⁶C₀₋₆alkyl, C₂₋₆alkenylOC₀₋₆alkyl or hydroxyC₁₋₆alkyl, and
R⁴ is absent.

25.(new) A compound according to claim 21, wherein:

ring P is C₆₋₁₀aryl, C₅₋₆heteroaryl, which ring P may be fused with C₃₋₇heterocycloalkyl;

R¹ is NO₂, NH₂, halo, N(C₁₋₆alkyl)₂, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, phenylC₀₋₆alkyl, C₃₋₇heterocycloalkylC₀₋₆alkyl, C₁₋₆alkylOC₀₋₆alkyl or C₁₋₆alkylSC₀₋₆alkyl;

n is 1, 2 or 3;

X is O, N or S;

R^4 is C_{1-4} alkyl or hydroxy C_{1-6} alkyl, or is absent when X is N;

R^3 is C_{1-6} alkyl, NR^5R^6CO , $NR^5R^6C_{0-6}$ alkyl, C_{2-6} alkenyl OC_{0-6} alkyl or hydroxy C_{1-6} alkyl;

R^5 and R^6 are independently selected from H, C_{6-10} aryl, C_{5-6} heteroaryl, C_{1-4} alkyl SO_2 and C_{1-3} alkyl CO ;

R^7 and R^8 are independently selected from H, halo and cyano and wherein:

any alkyl, phenyl, heteroaryl group may be substituted with one or more A where A at each occurrence is independently selected from OH, NO_2 , halo or C_{1-6} alkyl OC_{0-6} alkyl.

26.(new) A compound according to claim 25, wherein:

X is N;

R^3 is H or C_{1-6} alkyl; and

R^4 is H.

27.(new) A compound according to claim 25, wherein:

X is N;

R^3 is C_{1-6} fluoroalkyl and

R^4 is H.

28.(new) A compound according to claim 21, wherein X is S and R^3 is methyl.

29.(new) A compound according to claim 21, wherein X is O and R^3 is C_{1-6} alkyl or hydroxy C_{1-6} alkyl.

30.(new) A compound according to claim 21, wherein X is N, R^3 is C_{1-6} alkyl and R^4 is C_{1-6} alkyl or hydroxy C_{1-6} alkyl.

31.(new) A compound according to claim 21, wherein:

ring P is phenyl, and R¹ is NO₂, NH₂, halo, N(C₁₋₆alkyl)₂, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, phenylC₀₋₆alkyl, C₅₋₆heteroarylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl, C₃₋₇heterocycloalkylC₀₋₆alkyl, C₁₋₆alkylOC₀₋₆alkyl, C₁₋₆alkylSC₀₋₆alkyl or C₁₋₆alkylNC₀₋₆alkyl optionally substituted with one or more A.

32.(new) A compound according to claim 21, wherein

ring P is pyrazolyl, pyridine, benzodioxolane, furan, thiophene or naphthalene.

33.(new) A compound according to claim 21, selected from the group consisting of:

4-tert-Butoxy-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
4-Bromo-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-iodobenzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-morpholin-4-ylbenzamide;
N-{2-[(Allyloxy)methyl]-1,3-benzothiazol-5-yl}-4-morpholin-4-ylbenzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-1-phenyl-5-propyl-1H-pyrazole-4-carboxamide;
1-tert-Butyl-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-3-methyl-1H-pyrazole-5-carboxamide;
4-(Ethoxymethyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-1-phenyl-1H-pyrazole-5-carboxamide;
4-Bromo-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-2-methylbenzamide;
4-tert-Butoxy-N-(2-methyl-1,3-benzoxazol-5-yl) benzamide;
N-(4-Bromo-2-methyl-1,3-benzothiazol-5-yl)-4-tert-butylbenzamide ;
4-tert-Butyl-N-(4,7-dibromo-2-methyl-1,3-benzothiazol-5-yl)benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
4-Iodo-N-(2-methyl-5-benzothiazolyl)benzamide;
4-(tert-Butoxymethyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-(1,2-Dimethyl-1H-benzimidazol-5-yl)-4-iodobenzamide;

N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-isopropoxybenzamide;
4-Bromo-2-chloro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
4-Bromo-2-fluoro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-(morpholin-4-ylmethyl)benzamide;
3-Fluoro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-4-(trifluoromethyl)benzamide;
4-tert-Butoxy-N-[4-chloro-2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
4-(tert-Butoxymethyl)-N-[4-chloro-2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
3-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-4-trifluoromethyl-benzamide;
2-tert-Butyl-5-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-4-trifluoromethyl-benzamide;
2-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-3-trifluoromethyl-benzamide;
4-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-3-trifluoromethyl-benzamide;
3,4-Dimethyl-N-(2-methyl-benzothiazol-5-yl)-benzamide;
2,2-Difluoro-benzo[1,3]dioxole-5-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-6-trifluoromethyl-nicotinamide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-4-propyl-benzamide;
3-Iodo-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
2,5-Dimethyl-furan-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
5-tert-Butyl-2-methyl-furan-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
4-Bromo-3-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
3,4-Difluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
3-Chloro-2-fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
Pyridine-2-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
3-Fluoro-4-trifluoromethyl-N-(2-trifluoromethyl-1H-benzimidazol-5-yl)-benzamide;
2-Fluoro-5-trifluoromethyl-N-(2-trifluoromethyl-1H-benzimidazol-5-yl)-benzamide;
4-Chloro-N-(2-methyl-benzothiazol-5-yl)-benzamide;
1-Phenyl-5-trifluoromethyl-1H-pyrazole-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;

2,3-Difluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-4-trifluoromethyl-benzamide;
3-Fluoro-4-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Ethyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-methyl-1,3-benzooxazol-5-yl)-benzamide;
Biphenyl-4-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
3-Bromo-thiophene-2-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
4-Bromo-2-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butoxy-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
2-Chloro-3,4-dimethoxy-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Iodo-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Amino-N-(2-methyl-1,3-benzothiazol-5-yl)-3-nitro-benzamide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-4-vinyl-benzamide;
4-Ethoxy-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Ethylsulfanyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Dimethylamino-naphthalene-1-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2-Fluoro-6-iodo-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Ethoxymethyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-4-trifluoromethoxy-benzamide;
4-Chloro-3-fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-formyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-hydroxymethyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-([(2-methoxypyridin-3-yl)amino]methyl)-1,3-benzothiazol-5-yl)benzamide;
4-tert-Butyl-N-[2-(1-hydroxyethyl)-1,3-benzothiazol-5-yl]benzamide;
4-tert-Butyl-N-{2-[(1H-pyrazol-3-ylamino)methyl]-1,3-benzothiazol-5-yl}benzamide;
4-(1,1-Dimethylethyl)-N-[2-[(4-nitrophenyl)amino]methyl]-5-benzothiazolyl]-benzamide;
N-[2-(Aminomethyl)-1,3-benzothiazol-5-yl]-4-tert-butylbenzamide;
4-tert-Butyl-N-(2-([(methylsulfonyl)amino]methyl)-1,3-benzothiazol-5-yl)benzamide;
N-{2-[(Acetylamino)methyl]-1,3-benzothiazol-5-yl}-4-tert-butylbenzamide;
5-[(4-tert-Butylbenzoyl)amino]-1,3-benzothiazole-2-carboxamide;
N-1,3-Benzothiazol-5-yl-4-tert-butylbenzamide;
4-Chloro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;

1-(4-chlorophenyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-5-propyl-1H-pyrazole-4-carboxamide;

1-(4-Chlorophenyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-(2,4-Dimethyl-1,3-benzothiazol-5-yl)-4-(1-hydroxy-1-methylethyl)benzamide;

4-(Hydroxymethyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;

4-tert-Butyl-N-(4-cyano-2-methyl-1,3-benzothiazol-5-yl)benzamide;


4-tert-Butyl-N-[2-(hydroxymethyl)-1,3-benzoxazol-5-yl]benzamide;

5-(4-tert-Butylbenzoylamino)-1,3-benzothiazol-2-ylcarboxylic acid, and

4-tert-Butyl-N-(2-methoxycarbonyl-1,3-benzothiazol-5-yl)-benzamide;

or a salt, solvate or solvated salt thereof.

34.(new) A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of compound having the formula I



I

wherein:

ring P is C₆₋₁₀aryl, C₃₋₇cycloalkyl, C₅₋₆heteroaryl, which ring P may be fused with phenyl, C₅₋₆heteroaryl, C₃₋₇cycloalkyl or C₃₋₇heterocycloalkyl;

R¹ is NO₂, NH₂, halo, N(C₁₋₆alkyl)₂, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, phenylC₀₋₆alkyl, C₅₋₆heteroarylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl, C₃₋₇heterocycloalkylC₀₋₆alkyl, C₁₋₆alkylOC₀₋₆alkyl, C₁₋₆alkylSC₀₋₆alkyl or C₁₋₆alkylNC₀₋₆alkyl;

n is 1, 2, 3, 4 or 5;

X is O, S or N;

R⁴ is H, C₁₋₄alkyl, hydroxyC₁₋₆alkyl or C₁₋₆alkylOC₁₋₆alkyl, or is absent when X is N;

R³ is H, C₁₋₆alkyl, C₁₋₆haloalkyl, R⁵OC₁₋₆alkyl, R⁵O(CO), R⁵CO, NR⁵R⁶CO, NR⁵R⁶C₀₋₆alkyl, C₂₋₆alkenylOC₀₋₆alkyl or hydroxyC₁₋₆alkyl;

R^5 and R^6 are at each occurrence independently selected from H, C_{1-6} alkyl, C_{6-10} aryl, C_{5-6} heteroaryl, C_{1-4} alkylSO₂ and C_{1-3} alkylCO;

R^7 and R^8 are independently selected from H, C_{1-6} alkyl, halo, cyano, C_{1-6} alkylOC₀₋₆alkyl, OH, NO₂ and COR⁹, N(R⁹)₂; and

R^9 is H or C_{1-6} alkyl;


wherein any alkyl, alkylOalkyl, haloalkyl, haloalkylO, phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group may be substituted with one or more A, where A at each occurrence is independently selected from OH, NO₂, R⁹CO, R⁹O(CO), N(R⁹)₂, R⁹S, R⁹SO₂, halo or C_{1-6} alkylOC₀₋₆alkyl,

or a salt, solvate or solvated salt thereof,

in association with one or more pharmaceutically acceptable diluents, excipients or inert carriers.

35.(new) A method of treating VR1 mediated disorders, acute and chronic pain disorders, acute and chronic neuropathic pain or acute and chronic inflammatory pain comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 34.

36.(new) A method of treatment of VR1 mediated disorders, acute and chronic pain disorders, acute and chronic neuropathic pain, acute or chronic inflammatory pain, or respiratory diseases, comprising administering to a mammal a therapeutically effective amount of compound having the formula I



I

wherein:

ring P is C_{6-10} aryl, C_{3-7} cycloalkyl, C_{5-6} heteroaryl, which ring P may be fused with phenyl, C_{5-6} heteroaryl, C_{3-7} cycloalkyl or C_{3-7} heterocycloalkyl;

R^1 is NO_2 , NH_2 , halo, $\text{N}(\text{C}_{1-6}\text{alkyl})_2$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{phenylC}_{0-6}\text{alkyl}$, $\text{C}_{5-6}\text{heteroarylC}_{0-6}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkylC}_{0-6}\text{alkyl}$, $\text{C}_{3-7}\text{heterocycloalkylC}_{0-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylSC}_{0-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkylNC}_{0-6}\text{alkyl}$;

n is 1, 2, 3, 4 or 5;

X is O, S or N;

R^4 is H, $\text{C}_{1-4}\text{alkyl}$, $\text{hydroxyC}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkylOC}_{1-6}\text{alkyl}$, or is absent when X is N;

R^3 is H, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{R}^5\text{OC}_{1-6}\text{alkyl}$, $\text{R}^5\text{O}(\text{CO})$, R^5CO , $\text{NR}^5\text{R}^6\text{CO}$, $\text{NR}^5\text{R}^6\text{C}_{0-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenylOC}_{0-6}\text{alkyl}$ or $\text{hydroxyC}_{1-6}\text{alkyl}$;

R^5 and R^6 are at each occurrence independently selected from H, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{6-10}\text{aryl}$, $\text{C}_{5-6}\text{heteroaryl}$, $\text{C}_{1-4}\text{alkylSO}_2$ and $\text{C}_{1-3}\text{alkylCO}$;

R^7 and R^8 are independently selected from H, $\text{C}_{1-6}\text{alkyl}$, halo, cyano, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, OH, NO_2 and COR^9 , $\text{N}(\text{R}^9)_2$; and

R^9 is H or $\text{C}_{1-6}\text{alkyl}$;

wherein any alkyl, alkylOalkyl, haloalkyl, haloalkylO, phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group may be substituted with one or more A, where A at each occurrence is independently selected from OH, NO_2 , R^9CO , $\text{R}^9\text{O}(\text{CO})$, $\text{N}(\text{R}^9)_2$, R^9S , R^9SO_2 , halo or $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$,

or a salt, solvate or solvated salt thereof.

37.(new) The method according to Claim 36 wherein said mammal is a human.

38.(new) A compound selected from the group consisting of

Allyl (5-amino-1,3-benzothiazol-2-yl)methyl carbonate;

4-tert-Butyl-N-(2-formyl-1,3-benzothiazol-5-yl)-benzamide;

4-Bromo-2-methyl-benzothiazol-5-ylamine, and

4-Chloro-2-methyl-benzothiazole-5-ylamine.

39.(new) A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of the group consisting of:

4-tert-Butoxy-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;

4-Bromo-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-iodobenzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-morpholin-4-ylbenzamide;
N-{2-[(Allyloxy)methyl]-1,3-benzothiazol-5-yl}-4-morpholin-4-ylbenzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-1-phenyl-5-propyl-1H-pyrazole-4-carboxamide;
1-tert-Butyl-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-3-methyl-1H-pyrazole-5-carboxamide;
4-(Ethoxymethyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-1-phenyl-1H-pyrazole-5-carboxamide;
4-Bromo-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-2-methylbenzamide;
4-tert-Butoxy-N-(2-methyl-1,3-benzoxazol-5-yl) benzamide;
N-(4-Bromo-2-methyl-1,3-benzothiazol-5-yl)-4-tert-butylbenzamide ;
4-tert-Butyl-N-(4,7-dibromo-2-methyl-1,3-benzothiazol-5-yl)benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
4-Iodo-N-(2-methyl-5-benzothiazolyl)benzamide;
4-(tert-Butoxymethyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-(1,2-Dimethyl-1H-benzimidazol-5-yl)-4-iodobenzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-isopropoxybenzamide;
4-Bromo-2-chloro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
4-Bromo-2-fluoro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
N-[2-(Hydroxymethyl)-1,3-benzothiazol-5-yl]-4-(morpholin-4-ylmethyl)benzamide;
3-Fluoro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-4-(trifluoromethyl)benzamide;
4-tert-Butoxy-N-[4-chloro-2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
4-(tert-Butoxymethyl)-N-[4-chloro-2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
3-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-4-trifluoromethyl-benzamide;
2-tert-Butyl-5-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-4-trifluoromethyl-benzamide;
2-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-3-trifluoromethyl-benzamide;

4-Fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-3-trifluoromethyl-benzamide;
3,4-Dimethyl-N-(2-methyl-benzothiazol-5-yl)-benzamide;
2,2-Difluoro-benzo[1,3]dioxole-5-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-6-trifluoromethyl-nicotinamide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-4-propyl-benzamide;
3-Iodo-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
2,5-Dimethyl-furan-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
5-tert-Butyl-2-methyl-furan-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
4-Bromo-3-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
3,4-Difluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
3-Chloro-2-fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
Pyridine-2-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
3-Fluoro-4-trifluoromethyl-N-(2-trifluoromethyl-1H-benzimidazol-5-yl)-benzamide;
2-Fluoro-5-trifluoromethyl-N-(2-trifluoromethyl-1H-benzimidazol-5-yl)-benzamide;
4-Chloro-N-(2-methyl-benzothiazol-5-yl)-benzamide;
1-Phenyl-5-trifluoromethyl-1H-pyrazole-3-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2,3-Difluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-4-trifluoromethyl-benzamide;
3-Fluoro-4-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Ethyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-methyl-1,3-benzooxazol-5-yl)-benzamide;
Biphenyl-4-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
3-Bromo-thiophene-2-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
4-Bromo-2-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butoxy-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
2-Chloro-3,4-dimethoxy-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Iodo-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Amino-N-(2-methyl-1,3-benzothiazol-5-yl)-3-nitro-benzamide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-4-vinyl-benzamide;
4-Ethoxy-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;

4-Ethylsulfanyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Dimethylamino-naphthalene-1-carboxylic acid (2-methyl-1,3-benzothiazol-5-yl)-amide;
2-Fluoro-6-iodo-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-Ethoxymethyl-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
N-(2-Methyl-1,3-benzothiazol-5-yl)-4-trifluoromethoxy-benzamide;
4-Chloro-3-fluoro-N-(2-methyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-formyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-hydroxymethyl-1,3-benzothiazol-5-yl)-benzamide;
4-tert-Butyl-N-(2-[(2-methoxypyridin-3-yl)amino]methyl)-1,3-benzothiazol-5-yl)benzamide;
4-tert-Butyl-N-[2-(1-hydroxyethyl)-1,3-benzothiazol-5-yl]benzamide;
4-tert-Butyl-N-{2-[(1H-pyrazol-3-ylamino)methyl]-1,3-benzothiazol-5-yl}benzamide;
4-(1,1-Dimethylethyl)-N-[2-[(4-nitrophenyl)amino]methyl]-5-benzothiazolyl]-benzamide;
N-[2-(Aminomethyl)-1,3-benzothiazol-5-yl]-4-tert-butylbenzamide;
4-tert-Butyl-N-(2-[(methylsulfonyl)amino]methyl)-1,3-benzothiazol-5-yl)benzamide;
N-{2-[(Acetylamino)methyl]-1,3-benzothiazol-5-yl}-4-tert-butylbenzamide;
5-[(4-tert-Butylbenzoyl)amino]-1,3-benzothiazole-2-carboxamide;
N-1,3-Benzothiazol-5-yl-4-tert-butylbenzamide;
4-Chloro-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
1-(4-chlorophenyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-5-propyl-1H-pyrazole-4-carboxamide;
1-(4-Chlorophenyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(2,4-Dimethyl-1,3-benzothiazol-5-yl)-4-(1-hydroxy-1-methylethyl)benzamide;
4-(Hydroxymethyl)-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]benzamide;
4-tert-Butyl-N-(4-cyano-2-methyl-1,3-benzothiazol-5-yl)benzamide;
4-tert-Butyl-N-[2-(hydroxymethyl)-1,3-benzoxazol-5-yl]benzamide;
5-(4-tert-Butylbenzoylamino)-1,3-benzothiazol-2-ylcarboxylic acid, and
4-tert-Butyl-N-(2-methoxycarbonyl-1,3-benzothiazol-5-yl)-benzamide;

or a salt, solvate or solvated salt thereof,

in association with one or more pharmaceutically acceptable diluents, excipients or inert carriers.

40.(new) A method of treating VR1 mediated disorders, acute and chronic pain disorders, acute and chronic neuropathic pain or acute and chronic inflammatory pain comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 39.